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Results: 
Lived Died No 8hock Shock 
Induced at RV Apex 75% 73% 83% 71% 
Induced by $2/$2S3 48% 30% 20% 52%' 
Drive cycle (ms) 400 ;t. 67 433 :~ 83 421:1; 07 474 ± 82' 
Monomorphlc VT 88% 84% 86% a1% 
RBBB morphology 81% 70% ."J 0 % 71%" 
~lperi0r Axi~ 55% 46% (]0% 47% 
$BP in VT (mmHg) 42 ,~ 35 44 ;l: 33 ~18 ± 30 49 ± 34 
VT cycle length (m,) 208 ~4S 254 ~: 47 254±40 251 ~: 4S 
~lpont, lermlnt~tlon S% 11% 10"~ 13% 
(' denotes p ~ 0,0~t) 
Conclusions: In thle high.risk population EP~i variables do not predict 
cardiac death; IlOWOVer, o~se of induolblllty (longer drive cycle length and 
1-2 oxtrastlmull) of VT and a RBBD morphology of the Induced VT was 
associated with leD shook(a) on follow.up, 
[ 1073-1751 Long-term Survival In the Antlarrhythmlce 
Ver~ua Implantable DMIbrll latom (AVID) Reglatry 
J,L, Anderson, The AVID Investigators, Unlwrslty of W~shing~on, S~lftle, 
WA, USA 
Background: AVID was e randomized trial comparing treatment with im, 
ptant~ble defibrillators vs antlarrhylhmlo drags tn ple with life-threatening 
ventrlcuhe arrhythmlas (VA), AVID also maintained a Reglefry on all pts wits 
any #gstalned VA or unexplained syncope (arrhythmla typos A-G) amenable 
to a treatment choloe aa well aa those VA (typos A-C) also eligible for the trial, 
The AVID Registry thus Included both randomized pie and those excluded 
from the main trial for any reason, 
Mefhod~: Of 6063 pts were screened. 4623 were registered, end 1016 
wore randomized, To compare mortality risk among VA types, follow-up was 
obtained on 2953 Regletry pts using the National Death Index determination 
of vital statue as of December, lg95, 
R~uff~: Mortality rates by VA type, nf n menn fnllnw-up of 11 7 ~ 80 (SD) 
moo, were: 
Ar~'hythmIR "hjpe N Do(ribs 1 
(A): VF et~tdl~c ,,lrmst 948 ~ 132 (t4%) 
(0): Syncop~l VT 399 ~ 65 (10%) 
(C): Symptomatic VT (EF : 0,40) 586 ~ 76 (13%) 
tO): Symptom~t¢ VT (EFT 040) t 58 e (6%) 
rE): Asymptomatic VT 3;'3 50 (13%) 
(F): VT-VF (Irnnsiont/corroctablo) 216 29 (13%) 
(G): Uno~(plnined syncope & inducible VT 273 25 (9'%) 
Global og,rank p= 0.0167; 1 crude do~th r~tos. Zrar.domtzod ~nd registry pts: VT, VF = 
vontrtc~,ll~r t chyc~rdio, f brillation: EF = ejection hnction 
Conclusion: Mortality in pts with serious VAs is high. "Lower risk" VAs 
(asymptomatlc VT and VTNF with correctable cause) have a similar mortality 
as "higher risk", AVID eligible VAs. Only those with VT and preserved EF 
(group D) showed a better prognosis. 
I 1 073-1 761 Dofetlllde: A New Class III Antlarrhythml¢ Drug 
Which Is Safe In Patients With Congestive Heart 
Failure 
C. To~p-Pedersen, The Danish Investigations of Arrhythmia nd Mortality 
ON Dofetilide (DIAMOND) study group. Dept. of Cardiology. Gentoffe 
University Hospital. Copenhagen. Denmark 
Backgreund: Arrhythmias are common in patients with congestive heart 
failure (CHF) but available antiarrhythmic drugs have severe side effects or 
the safety is questionable. 
Methods: In 34 Danish coronary care units 5548 consecutive patients 
admitted with newly developed or worsening congestive heart failure were 
screened and left ventricular function was assessed using echocardiography, 
Left ventricular dysfunction (wall motion index _< 1.2 corresponding to a left 
vontricular ejection fraction _<0.35) was found in 2552 patients, and of these 
1518 gave informed consent and were randomised to receive dofetilide or 
placebo. Dofetilide was dosed between 0.25 mg and 1 mg daily depending on 
renal function and presence of atrial fibrillation. All patients were monitored 
with continuous telemet~ for the initial R days of the study. The primary end 
poitlt was ad cause mortality and minimum follow up was 1 year, 
Results: In the dofetilide group 311/762, 41% died and in the placebo 
group 317.,756. 42%. The overall risk reduction on dofetilide was 0.95 (95% 
contidence limits 0.81-1.11, p = 0.56). At one year there was a 1.7% lower 
mortality on dofetilide with 95% confidence limits of ± 4% 
Conclusions: These results demonstrate that treatment with dofetitide in 
CHF patients with I,~tt ventricular dysfunction was neutral with respect to all 
cause mortnti~, ,~nmp~red toplacebo. 
I 1073-1771 Treatment of Dyarhythmlae After CABG-Surgery 
With the Amlodarone-derlvetive E 047/1 
H. Gombotz, M, VIcenzi. E, Mahla, H, Metzler, Dept. of Anesthesiology and 
Intensive Care, University of Graz, Austria 
Background: Dysryhthmlas may Jeopardize patients immediately after CABG- 
surgery. The therapeutic regimen, however, Is under discussion end the 
seamh for an Ideal drug Iscontlnuing, Experimentally, the amiodamne.derlva. 
five E047/1, wl~h e half life of 6 hrs, reduced ventdcular ectoplea, markedly 
suppressed VF end did not influence conduction end hemodynemtce, Thte 
phnso II study of E04711 investigated tolemblllty end efflceW In the trsetment 
el postoperative dyerhythmiea, 
Patients and Mefhod~: After approval by the Ethics Commltt~ end written 
consent, 20 CAC3G.petlonte (moan ¢ SO 06 ~ 5 ym, 78 :E 11 ks) with 
postoparetive etr~el fibrillation and/or significant ventdcular ectop!es (PVC's =, 
5/mln, couplets, triplets, VT), EF > 40%, plasma levels of K* > 3,5 and Ms++ 
~, 0,8 mmol wore included In e prospective study. E047/1 wee administered 
by bolus (1 rsg/kg for 10 rain) end contlnuoue infusion (t mgrkg/hr for 2 hrs), 
In addition to etendercl monitoring, dysrhythmlee were recorded continuously 
(CER Patient Monitor, Hewlett Packerd)~ Using thermodilution technique, 
homodynamloa nd derived I~rsmetere were detem,~ioed before, 10, 20, 
30, 60 end 120 mio, effor drag initiation, ECG tracings were analyzed by a 
blinded investigator. Frtedman's ANOVA was used for statistics, P < 001 
was accepted ¢~e ignitic~llt, 
Results: In 17 pationte with ventrioular ecfopies, E 047/1 induced a 55% 
reduction el dysrhy~hmias after 15 rain increasing to e 93% reduction after 
60 rain. Heart rata (93 ~_ 11 bpm), PQ. (t 58 ± 22 me), QT-intervals (379 ± 33 
ms) and hemodYnemtoa did not change troro baseline, Atdal lionllstioo was 
converted to SA rhythm in 2 el 7 patients. No adverse reactions occurred+ 
Conclusions: E 047/1 appears to be n safe, effective and rapid acting drag 
for postoperative ventrioular dysrhythmiaa, 
11073:1781. IS Induction Of Very Rapid Sustained VT 
Signif icant In PaUents With Syncope? 
S. Mittal, K.M. Stein, SM. MarkowiIz, D.J Slotwiner, MJ. Wong, 
B.B. Lerman. The New York HospttaI.Cornell University Medical Center, 
New York. NY, USA 
ICD implantation has become accepted therapy (Rx) for pts with syncope 
and inducible ventdcular arrhythmias who do not have clinically documented 
VT. It is not known, however, whether the cycle length (CL) of induced VT at 
EPS is an important prognostic determinant in this population. Specdicatly, 
the prognostic significance of very rapid monomocphic VT (<250 ms), which 
can be considered a non-specific response to the stimulation pmtecol, is 
unknown in pts without documented VT. We evaluated 25 consecutive pts 
(21 M, ago 67 ± 11 years, EF 29 ± 11%) who received an ICD for syncope 
and inducible sustained VT. Pts were followed until their first arrhythmic event 
requinng ICD Rx. Flu was available in 21 pts; of the 4 pts lost to flu, 3 died 
of unknown c~use before their first ICD interrogation, g pls had VT or VF 
requiring appropriate ICD Rx. The 30, 90, and 360 day probability of requmng 
ICD Rx was 22%, 42% and 54%. Pts with induced VT <250 ms (n = 10) and 
~250 ms (n = 11 ) had a similar likelihood of events. 
90 t 
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]L~OU.OW.1LtP ~IOPtZliS) 
Conclusions: Pts with ICDs for syncope have a significant incidence of 
arrhythmic events requiring ICD Rx. Pts are likely to have events irmspectwe 
of the cycle length of induced VT. Very rapid monomorphic VT induced 
during EPS should not be considered a non-specific finding; aggressive Rx 
is warra~ ,ted in these p~s with syncope. 
